Get the Stockscreener App
40.10
1.67%
0.6672
Omnicell Inc stock is traded at $40.10, with a volume of 386.37K.
It is up +1.67% in the last 24 hours and down -7.56% over the past month.
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
See More
Previous Close:
$39.43
Open:
$39.51
24h Volume:
386.37K
Relative Volume:
0.79
Market Cap:
$1.81B
Revenue:
$1.08B
Net Income/Loss:
$-20.76M
P/E Ratio:
-87.17
EPS:
-0.46
Net Cash Flow:
$151.63M
1W Performance:
-10.89%
1M Performance:
-7.56%
6M Performance:
+2.66%
1Y Performance:
+23.51%
1-Day Range:
$38.40
$40.86
1-Week Range:
$38.40
$47.69
52-Week Range:
$25.12
$55.74
Omnicell Inc Stock (OMCL) Company Profile
Name
Omnicell Inc
Sector
Industry
Phone
(877) 415-9990
Address
4220 NORTH FREEWAY, FORT WORTH
Compare OMCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMCL
Omnicell Inc
|
40.12 | 1.81B | 1.08B | -20.76M | 151.63M | -0.46 |
|
VEEV
Veeva Systems Inc
|
236.80 | 38.87B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
73.26 | 12.92B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
79.23 | 10.88B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
67.66 | 10.23B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
111.74 | 9.71B | 1.15B | 96.70M | -161.99M | 1.09 |
Omnicell Inc Stock (OMCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-03-24 | Initiated | Barclays | Underweight |
| Nov-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-03-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-11-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Sep-26-23 | Reiterated | Wells Fargo | Underweight |
| Aug-02-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-23 | Downgrade | Wells Fargo | Overweight → Underweight |
| Feb-27-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-03-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-09-22 | Initiated | BofA Securities | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Mkt Perform |
| Dec-06-21 | Resumed | Wells Fargo | Overweight |
| Jun-09-21 | Initiated | JP Morgan | Neutral |
| May-24-21 | Initiated | BTIG Research | Buy |
| Feb-02-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-20 | Initiated | Berenberg | Buy |
| Dec-03-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Feb-07-20 | Reiterated | Dougherty & Company | Buy |
| Nov-21-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-19 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-07-19 | Reiterated | Dougherty & Company | Buy |
| Jun-29-18 | Resumed | The Benchmark Company | Buy |
| Sep-05-17 | Reiterated | The Benchmark Company | Buy |
| Jul-28-17 | Reiterated | Dougherty & Company | Buy |
| Apr-21-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-19-17 | Initiated | Dougherty & Company | Buy |
| Dec-06-16 | Reiterated | The Benchmark Company | Buy |
| Jul-07-16 | Reiterated | FBR Capital | Outperform |
| Mar-21-16 | Reiterated | Topeka Capital Markets | Buy |
| Jan-07-16 | Initiated | The Benchmark Company | Buy |
| Nov-16-15 | Reiterated | Topeka Capital Markets | Buy |
| Oct-30-15 | Reiterated | FBR Capital | Outperform |
| Sep-28-15 | Upgrade | Sidoti | Neutral → Buy |
| Jul-31-15 | Reiterated | Topeka Capital Markets | Buy |
View All
Omnicell Inc Stock (OMCL) Latest News
Omnicell (NASDAQ:OMCL) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Omnicell (NASDAQ:OMCL) Shares Gap Down After Earnings Miss - MarketBeat
Omnicell (NASDAQ:OMCL) Could Be Struggling To Allocate Capital - Yahoo Finance
Omnicell Inc (OMCL) Q4 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Omnicell Inc (OMCL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Omnicell Reports Strong Q4 2024 Financial Results - TipRanks
Benchmark Reaffirms Buy Rating for Omnicell (NASDAQ:OMCL) - MarketBeat
Omnicell projects $1.105M to $1.155M revenue growth in 2025 with XT Amplify momentum - MSN
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates - MSN
Omnicell (NASDAQ:OMCL) Issues Q1 2025 Earnings Guidance - MarketBeat
Omnicell Inc (OMCL) Q4 2024 Earnings: EPS of $0.34 Beats Estimat - GuruFocus.com
Omnicell (NASDAQ:OMCL) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations By Stock Story - Investing.com Canada
Omnicell: Q4 Earnings Snapshot - mySA
Omnicell: Q4 Earnings Snapshot -February 06, 2025 at 07:11 am EST - Marketscreener.com
Omnicell (NASDAQ:OMCL) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations - Yahoo Finance
Omnicell Q4 earnings beat, but stock falls on weak guidance By Investing.com - Investing.com Nigeria
Omnicell Q4 earnings beat, but stock falls on weak guidance - Investing.com
(OMCL) OMNICELL INC. Sees Q1 Revenue Range $255M$265M -February 06, 2025 at 06:41 am EST - Marketscreener.com
(OMCL) OMNICELL INC. Forecasts Fiscal Year 2025 Adjusted EPS Range $1.65$1.85 - Marketscreener.com
Earnings Flash (OMCL) OMNICELL INC. Reports Q4 Revenue $306.9M, vs. FactSet Est of $300M - Marketscreener.com
Earnings Flash (OMCL) OMNICELL INC. Posts Q4 Adjusted EPS $0.60, vs. FactSet Est of $0.58 - Marketscreener.com
Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results - Business Wire
Medication Management Market Is Booming So Rapidly | Omnicell, - openPR
Earnings To Watch: Omnicell (OMCL) Reports Q4 Results Tomorrow - Yahoo Finance
Assessing Omnicell: Insights From 4 Financial Analysts - Benzinga
Medicine Compounding Robot Market Booming Trends: Future - openPR
Q2 Earnings Forecast for Omnicell Issued By Zacks Research - MarketBeat
Zacks Research Has Bullish Estimate for Omnicell Q1 Earnings - MarketBeat
Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down - MSN
U.S. Pharmacy Automation Devices Market May Set Epic Growth Story | Yuyama, Baxter, Omnicell - openPR
SteelPeak Wealth LLC Invests $635,000 in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Is Omnicell Stock a Solid Pick for Your Portfolio Right Now? - MSN
Owensboro Health to Deploy Omnicell’s Technology-Enabled Services to Improve Safety and Efficiency in Medication Management - Marketscreener.com
Global Surgery Center Software Market Size, Share and Forecast - openPR
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate - Simply Wall St
How to Take Advantage of moves in (OMCL) - Stock Traders Daily
SG Americas Securities LLC Acquires 14,202 Shares of Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Exchange Traded Concepts LLC Grows Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Zacks Industry Outlook Enovis, Omnicell and Phreesia - Zacks Investment Research
Zacks Industry Outlook Enovis, Omnicell And Phreesia - Barchart
3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects - Yahoo Finance
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC - Zacks Investment Research
Omnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Assenagon Asset Management S.A. Cuts Holdings in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Automated Dispensing Machines Market 2024-2031: Global - openPR
Arkadios Wealth Advisors Boosts Position in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Where are the Opportunities in (OMCL) - Stock Traders Daily
Pharmacy Automation Market Size Trends, Regional Dynamics, and Emerging Growth Factors in Key Industries Leading to 2027 - Barchart
Pharmacy Automation Market Generated Opportunities, Future Scope (2024-2031) | Swisslog Healthcare, Omnicell, Inc. - openPR
Omnicell Sets Q4 and Full Year 2024 Earnings Release Date for February 6 - StockTitan
Wells Fargo & Company Cuts Omnicell (NASDAQ:OMCL) Price Target to $40.00 - MarketBeat
Omnicell Inc Stock (OMCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.60%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):